StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
INBS$2.36+0.00%
Fair $2.36+0.0%

INBS

Intelligent Bio Solutions Inc.

Healthcare / Medical DevicesNasdaqCM

$2.36

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $2.36Fund rank 29/100 · Data gapFallback financials|
SA 9/F
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-9.9M · quality 53.7/100

Data gap 29/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 49/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

9/100

F

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 6Warnings: 1unknown: 6
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -3.5%, below the 5% threshold
Thesis & Journal · INBSLocal privado en este navegador · Intelligent Bio Solutions Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$5M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-352.7%

↓

Gross Margin

40.8%

↓

Debt/Equity

N/A

•
No hay histórico de precio usable para pintar el gráfico TradingView.

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2020–2025 · 5 años de histórico normalizado

Revenue CAGR

+74.5%

FCF CAGR

—

FCF margin

-324.6%

FCF / Net income

0.94x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $3.1M · net income $-10.6M · FCF $-9.9M

2020-FY → 2025-FY

Gross margin

40.8%— pts

Operating margin

-348.7%+1165.0% pts

Net margin

-346.2%+1330.0% pts

FCF margin

-324.6%— pts
MetricTTM
2025
2024
2023
2022
2021
2020
Income Statement
Revenue$3.1M$3.1M$3.1M$1.3M$437146.00$2.0M$188744.00
Net Income$-10.6M$-10.6M$-10.2M$-10.6M$-8.3M$-7.0M$-3.2M
EBITDA$-9.7M$-9.7M$-9.3M$-11.8M———
EPS-2.00-2.00-6.38-127.00-11.33-0.68—
Gross Margin40.8%40.8%45.8%26.0%———
Operating Margin-348.7%-348.7%-330.5%-1002.1%-1907.1%-281.4%-1513.7%
Net Margin-346.2%-346.2%-326.4%-845.9%-1900.1%-355.3%-1676.2%
Cash Flow
Free Cash Flow$-9.9M$-9.9M$-9.8M————
Returns
ROE-352.7%-352.7%-121.9%-279.9%-125.4%-46.7%61.0%
Growth & Yield
Revenue Growth-1.9%-1.9%147.6%187.5%-77.9%949.3%—
EPS Growth68.7%68.7%95.0%-1020.9%-1566.2%——

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total n/d
Return attribution requires positive start and end prices.

Unavailable: positive start/end prices are required.